Utility of tau biomarkers for detecting clinical outcomes in preclinical Alzheimer's disease
Biomarkers based on plasma p-tau217 levels and visual assessments of tau-PET demonstrate differential prognostic capabilities, with positive visual tau-PET reads emerging as a superior predictor of cognitive decline and neurodegeneration, even at preclinical AD stages.
Authors
- Miguel A. Labrador‐Espinosa (ORCID: https://orcid.org/0000-0003-3576-1777)
- Alexis Moscoso (ORCID: https://orcid.org/0000-0003-0170-036X)
- Michael Schöll (ORCID: https://orcid.org/0000-0001-7800-1781)
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
Institutions
- Sahlgrenska University Hospital (SE)
- LMU Klinikum (DE)
- Wallenberg Wood Science Center (SE)
- University College London (GB)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_102890
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00